# Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

> **NCT00509236** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 129 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- End-Stage Kidney Disease

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Glipizide

## Key facts

- **NCT ID:** NCT00509236
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-19
- **Primary completion:** 2011-03-14
- **Final completion:** 2011-03-14
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509236, "Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00509236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*